Relieves pain of osteoarthritis of joints amenable. ANDA 209903, held by Cipla. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 209903 (Diclofenac Sodium), held by Cipla, was first approved by FDA on Aug 3, 2018, with 1 approved supplement and 0 published complete response letters.
Diclofenac sodium is a non-steroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. Diclofenac sodium topical gel was not evaluated for use on joints of the spine, hip, or shoulder.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium1% · gel;topical | Diclofenac Sodium | OTC |
| Jul 15, 2024 | Supplement 10Manufacturing | Approved | |
| Aug 3, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters